August 2024 SCRI Release Copied
Trials and Trial Regimen Updates
The following updates were completed between July 19, 2024, through Aug. 22, 2024. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRI.DLEMRAnalysts@scri.com.
New Builds Completed
| Study Number | Notes for New Build |
| 24077 | USOR 24077 Axicabtagene Ciloleucel Day 0 + Prophylactic Dexamethasone Day 0,1,2
USOR 24077 Bridging R-CHOP Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone D1-5 Q21D USOR 24077 Bridging DA-EPOCH-R Rituximab + Etoposide + Doxorubicin + Vincristine D1-4 + Cyclophosphamide D5 + Prednisone D1- 5 Q21D USOR 24077 SOCT DA-EPOCH-R Rituximab + Etoposide + Doxorubicin + Vincristine D1-4 + Cyclophosphamide D5 + Prednisone D1-5 Q21D USOR 24077 SOCT R-CHOP Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone D1-5 Q21D |
| 24075 | USOR 24075 Trastuzumab (Herzuma) + Capecitabine D1-14 Q21D USOR 24075 Trastuzumab (Herzuma) + Eribulin D1,8 Q21D USOR 24075 Trastuzumab (Herzuma) + Gemcitabine D1,8 Q21D USOR 24075 Trastuzumab (Herzuma) + Vinorelbine D1,8 Q21D USOR 24075 Zanidatamab + Capecitabine D1-14 Q21D
USOR 24075 Zanidatamab + Eribulin D1,8 Q21D USOR 24075 Zanidatamab + Gemcitabine D1,8 Q21D USOR 24075 Zanidatamab + Vinorelbine D1,8 Q21D |
| 23083 | USOR 23083 Maintenance Pembrolizumab Q42D
USOR 23083 Pembrolizumab + Paclitaxel + Carboplatin Q21D USOR 23083 Pembrolizumab + Pemetrexed + Carboplatin Q21D USOR 23083 Volrustomig + Paclitaxel + Carboplatin Q21D USOR 23083 Volrustomig + Pemetrexed + Carboplatin Q21D |
| 23115 | USOR 23115 Volrustomig or Placebo Q21D |
| 24030 | USOR 24030 GYN 130 Phase III Doxorubicin Q21D USOR 24030 GYN 130 Phase III Paclitaxel D1,8,15 Q28D
USOR 24030 GYN 130 Phase III Sacituzumab Govitecan D1,8 Q21D |
| 23333 | USOR 22333 Tucatinib (BID) + Liposomal Doxorubicin Q28D |
Updated Reference Information
| Study Number | Updated Reference Information | Other Changes |
| 21304 | X | |
| 23243 | X | |
| 22022 | X | |
| 19062 | X | |
| 22326 | X | |
| 22133 | X | |
| 21468 | X | |
| 23051 | X | |
| 23288 | Dose escalation memo 1.8 to 2.7 mg | |
| 22322 | X | |
| 21304 | X | |
| 23292 | X | |
| 22106 | X | |
| 23292 | X | |
| 23212 | X | |
| 23048 | X | |
| 23016 | X | |
| 23048 | X | |
| 21365 | X | |
| 23120 | X |